Hotchkis & Wiley Capital Management LLC held its stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,900 shares of the company’s stock at the end of the first quarter. Hotchkis & Wiley Capital Management LLC’s holdings in Eli Lilly and were worth $2,263,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Sunbelt Securities Inc. increased its stake in shares of Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares in the last quarter. Pillar Pacific Capital Management LLC increased its stake in shares of Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after buying an additional 20 shares in the last quarter. Rehmann Capital Advisory Group increased its stake in shares of Eli Lilly and by 0.9% in the first quarter. Rehmann Capital Advisory Group now owns 5,026 shares of the company’s stock valued at $423,000 after buying an additional 43 shares in the last quarter. Alpha Windward LLC increased its stake in shares of Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares in the last quarter. Finally, Joel Isaacson & Co. LLC increased its stake in shares of Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares in the last quarter. 75.61% of the stock is owned by institutional investors and hedge funds.

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.23% on Wednesday, reaching $82.16. The company’s stock had a trading volume of 203,840 shares. The stock has a 50-day moving average price of $83.03 and a 200-day moving average price of $81.54. The company has a market capitalization of $86.68 billion, a price-to-earnings ratio of 35.55 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 earnings per share. On average, equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Position Held by Hotchkis & Wiley Capital Management LLC” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/09/eli-lilly-and-company-lly-position-held-by-hotchkis-wiley-capital-management-llc.html.

Several equities research analysts have weighed in on the company. Berenberg Bank reissued a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Cowen and Company raised their price target on Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a report on Monday, April 17th. Sanford C. Bernstein reissued an “outperform” rating and issued a $88.00 price target on shares of Eli Lilly and in a report on Sunday, May 21st. TheStreet downgraded Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. Finally, BMO Capital Markets reissued an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a report on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly and currently has an average rating of “Hold” and a consensus target price of $88.27.

In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the transaction, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock valued at $55,845,287 in the last three months. 0.20% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.